New Blood Test Predicts Lung Cancer Risk Years Early

A groundbreaking Australian-led study has identified a distinctive 14-protein 'blood signature' that can predict an individual's risk of developing lung cancer more than five years before a diagnosis is typically made. Published in the prestigious scientific journal *Cell*, these landmark findings offer a significant leap forward in the quest for early detection and prevention strategies for one of the world's deadliest cancers. The research was a collaborative effort involving the Francis Crick Institute and University College London (UCL), and was notably co-led by Dr. Clare Weeden, a laboratory head at Australia's Walter and Eliza Hall Institute of Medical Research (WEHI), who conducted a substantial part of the research during her tenure at the Crick. This international collaboration underscores the global implications of the discovery. The study utilized machine learning to meticulously analyze blood plasma protein data from over 48,000 participants in the UK Biobank, a vast biomedical database. The identified protein signature was then rigorously validated across eight international datasets, further strengthening the reliability and generalizability of the findings. Crucially, the researchers suggest that this blood signature does not originate directly from a developing tumor itself, but rather reflects an altered inflammatory environment within the lung that precedes the onset of cancer. This points to a 'pre-disease phase' where interventions might be most effective. The ability to detect this inflammatory signal years in advance could pave the way for identifying individuals who would benefit most from preventative drugs, even before any cancerous cells are detected. Current lung cancer screening programs, primarily employing low-dose computed tomography (LDCT), are typically restricted to high-risk groups, such as heavy smokers aged 50 to 70. The new blood signature, however, holds the potential to enable broader screening across a wider demographic, including non-smokers, who currently lack effective early detection tools. This is particularly significant given that around a quarter of lung cancer diagnoses in Australia, for instance, occur in individuals with no history of smoking. Environmental factors, such as exposure to air pollution from traffic and coal burning, are increasingly recognized as risk factors, even among non-smokers, and the study found the protein signature was elevated in people exposed to particulate air pollution. The implications for prevention are also considerable. Earlier work by the same lab demonstrated that air pollution exposure can trigger immune cells in the lung to release an inflammatory signal called interleukin-1 beta (IL-1β), which can activate dormant cells carrying cancer-causing mutations. In this latest study, blocking the IL-1β inflammatory signal in mice was shown to reduce early tumor development, suggesting a potential preventive treatment pathway for humans. Furthermore, a re-analysis of data from the CANTOS trial – which previously tested the IL-1β blocker canakinumab for cardiovascular disease and incidentally reported a reduction in lung cancer incidence – revealed that individuals with a high baseline 14-protein signature benefited most from the drug, experiencing a nearly 50% reduction in lung cancer risk. For an audience in India, these findings are highly relevant and critical. Lung cancer represents a major public health challenge in India, with cases projected to significantly increase from over 63,000 in 2015 to more than 81,000 by 2025. A grim statistic indicates that nearly 80-85% of lung cancer patients in India are diagnosed at an advanced stage, when curative therapies are often no longer feasible, leading to high mortality rates. Early detection is paramount for improving patient outcomes, as the five-year survival rate for localized lung cancer is significantly higher than for advanced stages. The elevated protein signature linked to air pollution is particularly pertinent for India, which grapples with some of the highest levels of air pollution globally. Dr. Abhishek Shankar, a radiation oncologist at AIIMS Delhi, emphasized that while this blood test should be seen as a risk-assessment tool rather than a definitive screening test, it is an important scientific advance. He also highlighted the necessity for these protein signatures to be validated in Indian populations before widespread application, acknowledging the unique demographic and environmental factors at play in the country. This research offers a beacon of hope for a future where lung cancer can be detected much earlier, potentially transforming prevention and treatment strategies worldwide and particularly impacting nations like India.

Frequently Asked Questions

Read Full Story on Quick Digest